TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03351296

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: Capecitabine 750 mg/m² twice daily, days 1-14
Study: NCT02137356

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: standard dose capecitabine
Description: 825 mg/m2 twice daily, 5 days a week (max dose 2000mg twice daily), only on days when radiation is delivered

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dose-escalated selinexor treatment
Description: Selinexor oral drug will be given twice weekly according to the dose escalation schedule described in the protocol. Selinexor will be started on the day radiation begins, until the end of week 6.
Study: NCT01902303

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Matching Placebo
Description: Sublingual micro dosing of placebo for 7 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BTL-TML-HSV
Description: Sublingual micro dosing of BTL-TML-HSV for 7 days
Study: NCT02362932

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sanitation
Description: Shared sanitation
Study: NCT01699685

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: QAB149
Description: Capsule form in blister packs inhaled with the Novartis Concept 1 SDDPI

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: QAB149
Description: Capsule form in blister packs inhaled with the Novartis Concept 1 SDDPI

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Capsule form in blister packs inhaled with the Novartis Concept 1 SDDPI

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: NVA237
Description: Capsule form in blister packs inhaled with the Novartis Concept 1 SDDPI
Study: NCT01599676

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Citrulline
Description: The subject will receive citrulline 10 g/day orally in the morning for 12 weeks.

Intervention type: DIETARY_SUPPLEMENT
Group type: SHAM_COMPARATOR
Intervention: Non essential amino acid
Description: Non essential amino acid supplementation
Study: NCT02821000

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Intravenous infusion
Study: NCT02255695

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: School-based exercise program
Description: The exercise program was applied, twice a week, for 8 weeks, with sessions of 50 minutes, in groups of 10 students. The exercise program was elaborate to restore muscular balance through flexibility, endurance and muscular strength. To promote flexibility stretching exercises for rotator neck muscles, lateral neck flexors, levator scapulae, upper trapezius, erector spinae, major and minor pectoralis, rhomboids, spinal lateral flexors, column rotators, piriformis, hamstrings, quadriceps, hip adductors and abductors were applied. Strengthening exercises were applied for the development of strength, endurance and control of deep flexor muscles of the cervical spine, stabilizers of the glenohumeral joint and scapula, abdominals, spine extensors and hip extensors.
Study: NCT02415803

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: low-dose ticagrelor
Description: 90 mg loading dose, then 45 mg twice daily for 5 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: conventional-dose ticagrelor
Description: 180 mg loading dose, then 90 mg twice daily for 5 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clopidogrel
Description: 300 mg loading dose, then 75 mg once daily for 5 days
Study: NCT01142687

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: dihydrocapsiate capsule
Description: * Group 1: 1 dihydrocapsiate capsule and 2 placebo capsules three times a day within 30 minutes before breakfast, lunch and dinner.~* Group 2: 3 dihydrocapsiate capsules three times per day within 30 minutes before breakfast, lunch and dinner~* Group 3: Placebo 3 capsules three times per day within 30 minutes before breakfast, lunch and dinner

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: dihydrocapsiate capsule
Description: * Group 1: 1 dihydrocapsiate capsule and 2 placebo capsules three times a day within 30 minutes before breakfast, lunch and dinner.~* Group 2: 3 dihydrocapsiate capsules three times per day within 30 minutes before breakfast, lunch and dinner~* Group 3: Placebo 3 capsules three times per day within 30 minutes before breakfast, lunch and dinner

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: dihydrocapsiate capsule
Description: * Group 1: 1 dihydrocapsiate capsule and 2 placebo capsules three times a day within 30 minutes before breakfast, lunch and dinner.~* Group 2: 3 dihydrocapsiate capsules three times per day within 30 minutes before breakfast, lunch and dinner~* Group 3: Placebo 3 capsules three times per day within 30 minutes before breakfast, lunch and dinner
Study: NCT04252118

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MSCs
Description: 3 times of MSCs(3.0\*10E7 MSCs intravenously at Day 0, Day 3, Day 6).
Study: NCT04594083

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Palm Stimulator
Description: The Palm Stimulator, developed by the present researchers for the first time, is 1.6 cm in diameter, 4 cm in length, and has a cylindrical, non-slippery structure for an easy grip to ensure maximum contact with the palm The Palm Stimulator consists of blunt protrusions that will provide a tactile stimulus on the palm. The blunt protrusions do not penetrate into the skin. The simulator design is based on the gate-control theory, which allows for a reduction in the perceived amount of pain experienced during injection by closing the pain gate in the spinal cord in creating a stimulus on the skin.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ShotBlocker
Description: ShotBlocker was placed in the ventrogluteal area properly 20 seconds before injection. It was fixed at the injection site until the injection process was completed.
Study: NCT01389284

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Naproxen Sodium ER (BAYH6689)
Description: 660 mg Naproxen Sodium extended release tablet, orally administered once daily for 24 hours

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Naproxen Sodium IR (Aleve, BAYH6689)
Description: 220 mg Naproxen Sodium instant release tablet, orally administered 3 times daily (TID) for 24 hours

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Naproxen Sodium ER Placebo
Description: Matching placebo of 660 mg Naproxen Sodium ER for 24 hours

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Naproxen Sodium ER Placebo
Description: Matching placebo of 660 mg Naproxen Sodium ER for 24 hours

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Naproxen Sodium IR Placebo
Description: Matching placebo of 220 mg Naproxen Sodium IR (Aleve) for 24 hours

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Naproxen Sodium IR Placebo
Description: Matching placebo of 220 mg Naproxen Sodium IR (Aleve) for 24 hours
Study: NCT02216877

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mablet 360 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mablet 360 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT04638504

Intervention type: OTHER
Intervention: ultrasonography
Description: vascular and adipose tissue measurement by ultrasonography

Intervention type: OTHER
Intervention: ultrasonography
Description: vascular and adipose tissue measurement by ultrasonography

Intervention type: OTHER
Intervention: ultrasonography
Description: vascular and adipose tissue measurement by ultrasonography

Intervention type: OTHER
Intervention: ultrasonography
Description: vascular and adipose tissue measurement by ultrasonography
Study: NCT00784927

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: rituximab

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dexamethasone

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lenalidomide
Study: NCT00371761

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pegylated interferon alfa-2b (PegIntron)
Description: Powder for injection in vials ( 100, and 120 microgram strengths), subcutaneous, dose of 1.5 micrograms/kg, weekly for up to 24 weeks
Study: NCT03351296

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide
Description: temozolomide 200 mg/m² once daily, days 10-14, every 28 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide
Description: temozolomide 200 mg/m² once daily, days 10-14, every 28 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: bevacizumab 5 mg/kg every 14 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: bevacizumab 5 mg/kg every 14 days
Study: NCT03369535

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: CARB rich diet
Description: Consumed CARB rich diet for 6 weeks with a washout period of at least 2 weeks before the next intervention

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: CARB rich diet
Description: Consumed CARB rich diet for 6 weeks with a washout period of at least 2 weeks before the next intervention

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: CARB rich diet
Description: Consumed CARB rich diet for 6 weeks with a washout period of at least 2 weeks before the next intervention

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: MUFA rich diet
Description: Consumed MUFA rich diet for 6 weeks with a washout period of at least 2 weeks before the next intervention

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: MUFA rich diet
Description: Consumed MUFA rich diet for 6 weeks with a washout period of at least 2 weeks before the next intervention

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: MUFA rich diet
Description: Consumed MUFA rich diet for 6 weeks with a washout period of at least 2 weeks before the next intervention

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: PROT rich diet
Description: Consumed PROT rich diet for 6 weeks with a washout period of at least 2 weeks before the next intervention

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: PROT rich diet
Description: Consumed PROT rich diet for 6 weeks with a washout period of at least 2 weeks before the next intervention

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: PROT rich diet
Description: Consumed PROT rich diet for 6 weeks with a washout period of at least 2 weeks before the next intervention
Study: NCT00070291

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclosporine
Description: Cyclosporine doses will be based on actual body weight unless actual body weight is \> 15 kg higher than the ideal body weight. Cyclosporine dose will be adjusted to maintain a trough whole blood level of 250-450 ng/mL during the high dose period (weeks 1 -6, starting dose will begin at cyclosporine 3 mg/kg by mouth two times a day (PO BID)) and 150-250 ng/mL during the maintenance period (weeks 7-36, maintenance dose will begin at cyclosporine 2 mg/kg PO BID) in the absence of renal toxicity
Study: NCT00371761

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Adefovir dipivoxil (adefovir)
Description: 10 mg adefovir dipivoxil (equivalent to 5.4.5 mg adefovir) tablets, oral, dose of 1 tablet per day for up to 48 weeks
Study: NCT03361176

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Injectable sodium deoxycholate
Description: Kybella(TM) alone: 2 mg/cm2 of Kybella(TM) with 0.2 mL of 1% lidocaine with no epinephrine plus 0.2cc saline to the non-TMC group to maintain equal concentrations in each injection so that the final Kybella concentration per vial will be 10mg/1.2mls or 1.6mg per 0.2 cc injection point will be delivered in up to 50 injections spaced 1.0 cm apart at 0.2 mL/injection for a total maximal dose of up to 100 mg of SDOC.

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Injectable sodium deoxycholate with Triamcinolone acetate
Description: Kybella(TM)+TMC at 1.0 mg/mL: 2.0 mL of 2 mg/cm2 of Kybella(TM) will be mixed with 0.2 mL of 10 mg/mL of triamcinolone acetate, 0.2 mL of 1% lidocaine with no epinephrine and then delivered in up to 50 injections spaced 1.0 cm apart at 0.2 mL/injection for a total dose of up to 100 mg of SDOC using a 30 gauge (or smaller) 0.5-inch needle. The final Kybella concentration per vial will be 10mg/1.2mls or 1.6mg per 0.2 cc injection point
Study: NCT02496507

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sit-stand workstation
Description: After baseline, each participant had a sit-stand workstation installed on their existing workplace desk. A single or dual monitor WorkFit-A with Worksurface+ workstation was installed, dependent on the number of monitors. The monitor(s) and keyboard were housed on the workstation and the workstation could be quickly raised up and down by hand to enable seated or standing work. Participants were not prescribed an amount of time to use the station. Ergotron Ltd provided and installed the workstations and gave participants basic face-to-face training and ergonomic information on correct use. Participants received a web link to manufacturer ergonomic guidelines via an email from the research team. After end-intervention data collection, manufacturer staff uninstalled the workstations.
Study: NCT03718299

Intervention type: DRUG
Group type: OTHER
Intervention: Injections of tildrakizumab
Description: given at Week 0, Week 4, Week 16, Week 28, Week 40 and Week 52
Study: NCT02111980

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: RF Assure Scanning
Description: CIED and temporary pacemaker patients will be scanned with RF surgical sponge detection wand and mat as well as with and without the RF sponge. The scanning will only be conducted on the device scheduled for removal. Patients will have device interrogated before and after scanning (for CIEDs) to determine if there have been any clinically significant changes in programming or settings due to scanning with RF technology. Vitals will be monitored and recorded before, during, and after scanning.
Study: NCT05142644

Intervention type: PROCEDURE
Intervention: ultrasound
Description: An extra ultrasound performed during pregnancy

Intervention type: PROCEDURE
Intervention: ultrasound
Description: An extra ultrasound performed during pregnancy
Study: NCT01862029

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Roflumilast
Description: Selective phosphodiesterase 4 (PDE4) inhibitor
Study: NCT01348971

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Sodium nitrate
Description: Preoperative oral administration of sodium nitrate. 700 mg the night before surgery and 700 mg three hours before surgery

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Sodium chloride
Description: Preoperative oral administration of sodium chloride the night before surgery and three hours before surgery
Study: NCT01389362

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Chinese herbal medicine (Radix Rehmanniae and Radix Astragali)
Description: 2 sachets to be taken daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo comparator
Description: 2 sachets to be taken daily
Study: NCT01728961

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Artemether/Lumefantrine (AL)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Artemether/Lumefantrine (AL)
Study: NCT03254147

Intervention type: DRUG
Intervention: warfarin
Description: warfarin
Study: NCT04306185

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: OVARIAN FRAGMENTATION
Description: BILATERAL OVARIAN CORTEX FRAGMENTATION USING LAPAROSCOPIC SCISSORS
Study: NCT04577339

Intervention type: PROCEDURE
Intervention: Laparotomy or laparoscopy
Description: Laparotomy is the opening of the abdominal cavity usually through a midline incision.~Laparoscopy is using minimal access keyhole surgery to perform the surgery instead of laparotomy Interventional radiology is the use of imaging to perform a procedure on the abdomen without surgery, for example, using ultrasound to guide a needle to drain an abscess Best supportive care is usually end-of-life care concentration on relieving symptoms rather than treating the cause.
Study: NCT00934323

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Amaryl M SR 1/500 mg
Description: single oral administration in period 1 for TR sequential group, and in period 2 for RT sequential group

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amaryl M SR 1/500 mg
Description: single oral administration in period 1 for TR sequential group, and in period 2 for RT sequential group

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Amaryl M SR 2/500 mg
Description: single oral administration in period 2 for TR sequential group, and in period 2 for RT sequential group

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amaryl M SR 2/500 mg
Description: single oral administration in period 2 for TR sequential group, and in period 2 for RT sequential group
Study: NCT01539096

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: tDCS: noninvasive brain stimulation
Description: TDCS is a method of noninvasive stimulation of the brain. Using electrodes placed in saline-soaked sponges, low level of direct current (1mA) is delivered over the scalp. This intervention is considered safe and noninvasive because it does not involve implantation or injection or any skin penetration. In the present study, tDCS will be delivered for 1 hr each day for 3 days a week for 5 weeks in conjunction with constraint-induced movement therapy for the affected hand.

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Constraint induced movement therapy (CIMT)
Description: Patients with stroke affecting the hand will receive constraint-induced movement therapy (CIMT) to re-train movements of the affected hand. Training will involve practicing tasks of daily living with qualified personnel. Training will be delivered for 1 hr each day for 3 days a week for 5 weeks. Patients will also be asked to use their affected hand in daily activities at home for 5 hrs a day while wearing a mitt on the unaffected hand.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Constraint induced movement therapy (CIMT)
Description: Patients with stroke affecting the hand will receive constraint-induced movement therapy (CIMT) to re-train movements of the affected hand. Training will involve practicing tasks of daily living with qualified personnel. Training will be delivered for 1 hr each day for 3 days a week for 5 weeks. Patients will also be asked to use their affected hand in daily activities at home for 5 hrs a day while wearing a mitt on the unaffected hand.

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Sham tDCS: placebo noninvasive brain stimulation
Description: Placebo set-up for noninvasive brain stimulation will be similar to that for the active tDCS; sponge electrodes would be placed on the scalp and connected to a batter-operated device. Patients will not receive the effective level of direct current as would delivered in active tDCS intervention. But patients will not be able to decipher whether they are receiving active or placebo tDCS.
Study: NCT02964039

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Error reduction
Description: During training sessions, a custom-built force-field will exert forces on the legs while participants walk. These forces will push the legs toward mechanically-appropriate mediolateral locations, having the effect of reducing the errors in foot placement that are often present among individuals who have experienced a stroke.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Error augmentation
Description: During training sessions, a custom-built force-field will exert forces on the legs while participants walk. These forces will push the legs away from mechanically-appropriate mediolateral locations, having the effect of amplifying the errors in foot placement that are often present among individuals who have experienced a stroke.

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Activity matched control
Description: During training sessions, participants will interface with a custom-built force-field while they walk. The force-field will essentially get out of the way, producing minimal forces on the legs, and having no direct effect on the errors in foot placement that are often present among individuals who have experienced a stroke.
Study: NCT00718081

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral sufentanil
Description: Oral dosage of sufentanil
Study: NCT01934816

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Intradermal injections of GLP-1 and its analogues
Description: native GLP-1,Exenatide (Byetta)and Liraglutide (Victoza) will be microinjected at the same visit in no particular order in all study arms

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Intradermal injections of GLP-1 and its analogues
Description: native GLP-1,Exenatide (Byetta)and Liraglutide (Victoza) will be microinjected at the same visit in no particular order in all study arms

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Intradermal injections of GLP-1 and its analogues
Description: native GLP-1,Exenatide (Byetta)and Liraglutide (Victoza) will be microinjected at the same visit in no particular order in all study arms
Study: NCT01899352

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Tracheostomy
Description: Percutaneous and surgical tracheostomies will be performed with the procedure currently available in clinical practice.
Study: NCT02577653

Intervention type: OTHER
Group type: OTHER
Intervention: Posturographic evaluation
Description: Subjects will undergo CDP testing using the modified Clinical Testing of Sensory Integration in Balance (mCTSIB) protocol. Subsequently, subjects will be asked to stand first on the right leg and then on the left leg with eyes open. Finally, subjects will be asked to perform 10 repetition of the squatting movement, with the operator pacing them (telling them when to start and when to stop the movements).
Study: NCT03254147

Intervention type: DRUG
Intervention: dabigatran
Description: Non-vitamin K dependent oral anti-coagulants (NOACs)

Intervention type: DRUG
Intervention: Apixaban
Description: Non-vitamin K dependent oral anti-coagulants (NOACs)

Intervention type: DRUG
Intervention: Edoxaban
Description: Non-vitamin K dependent oral anti-coagulants (NOACs)

Intervention type: DRUG
Intervention: Rivaroxaban
Description: Non-vitamin K dependent oral anti-coagulants (NOACs)
Study: NCT02197104

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: citocoline
Description: Ten subjects will receive 1,000mg once daily of citicoline. Each subject will stay on the study drug for 12 months. The outcome measures will be assessed at baseline and then again at the end of month 3, month 6, and month 12. The subjects will continue taking the same study drug at the same dose throughout the entire trial.